UKPDS - Modelling of cardiovascular risk assessment and lifetime simulation of outcomes

Diabetic Medicine

Volumn 25, Issue SUPPL. 2, 2008, Pages 41-46

  Adler, A I ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Epidemiology; Health economics; Modelling

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEATH; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPID BLOOD LEVEL; MATHEMATICAL MODEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK ASSESSMENT; SIMULATION; SMOKING; STROKE;

AGE FACTORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; SMOKING;

EID: 47649111861     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02498.x     Document Type: Review

References (49)

1. Meinert C, Knatterud G, Prout T, Klimt C. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970 19 : 789 830.
2. Department of Health Human Service National Institutes of Health National Heart Lung, and Blood Institute. Special emphasis panel on the prevention and treatment of cardiovascular disease in diabetes. Available at http://www.nhlbi.nih.gov/meetings/workshops/sepminfn.txt Last accessed 5 March 2008.
3. Kannel W, McGee D. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979 241 : 2035 2038.
4. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995 18 : 258 268.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 : 434 444.
6. Welborn T, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979 2 : 154 160.
7. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991 151 : 1141 1147.
8. Haffner SM, Mitchell BD, Stern MP, Hazuda HP. Macrovascular complications in Mexican Americans wtih Type II diabetes. Diabetes Care 1991 14 : 665 671.
9. Lehto S, Ronnemaa T, Haffner S, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997 48 : 1354 1359.
10. Turner R, Millns H, Neil H et al. UK Prospective Diabetes Study. UKPDS 23: Risk factors for coronary artery disease in non-insulin dependent diabetes. Br Med J 1997 316 : 823 828.
11. Barrett-Connor E, Wingard DL. Sex differences in ischemic heart idsease mortality in diabetics: A prospective population-based study. Am J Epidemiol 1983 118 : 489 496.
12. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004 141 : 421 431.
13. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 : 2005 2016.
14. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet Aug 2004 364 : 685 696.
15. Alliance for European Diabetes Research. Diabetes Research in Women 2007. Available at http://www.cdc.gov/diabetes/pubs/women/
16. Centers for Disease Control Prevention. Diabetes and Women's Health Across the Life Stages: A Public Health Perspective. Atlanta, GA : Centers for Disease Control and Prevention, 2001.
17. US Department of Health Human Services. The National Agenda for Public Health Action: The National Public Health Initiative on Diabetes and Women's Health. Available at http://www.hhs.gov/news/press/2003pres/20030325.html Last accessed 5 March 2008.
18. Alssema M, Dekker JM, Kuivenhoven J et al. Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovascular disease in women, but not in men, in Type 2 diabetes: the Hoorn Study. Diabet Med 2007 42 : 117 123.
19. Davis T, Millns H, Stratton I, Holman R, Turner R. Risk factors for stroke in Type 2 diabetes. Arch Intern Med 1999 159 : 1097.
20. Stratton I, Adler A, Neil H et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35). Br Med J 2000 321 : 405 411.
21. Adler A, Stevens R, Neil H, Holman R, Turner R. Hyperglycaemia and other potentially modifiable risk factors for peripheral vascular disease in Type 2 diabetes. Diabet Med 1999 16 : 16.
22. Selvin E, Erlinger T. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004 100 : 738 743.
23. Adler A, Neil H, Manley S, Holman R, Turner R. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the UK Prospective Diabetes Study (UKPDS 47). Am Heart J 1999 138 : 353 359.
24. Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med 2005 22 : 306 311.
25. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
26. Gale EA. The myth of the metabolic syndrome. Diabetologia 2005 48 : 1679 1683.
27. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in Type 2 diabetes mellitus: UK Prospective Diabetes Study 78. Circulation 2007 116 : 2119 2126.
28. Eddy DM. Clinical Decision Making; From Theory to Practice. Sudbury : Jones and Bartlett Publishers, 1996.
29. Stevens R, Adler A, Gray A, Briggs A, Holman R. Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 2000 50 : S5 13.
30. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes (UKPDS 38). Br Med J 1998 317 : 703 713.
31. The Epidemiology of Diabetes Interventions Complications (EDIC) Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes 4 years after a trial of intensive therapy. N Engl J Med 2000 342 : 381 389.
32. Stevens R, Coleman R, Adler A, Stratton I, Matthews D, Holman R. Risk factors for myocardial infarction case fatality and stroke case fatality in Type 2 diabetes - UKPDS 66. Diabetes Care 2004 27 : 201 207.
33. Stevens R, Kothari V, Adler A, Sratton I, Holman R. The UKPDS Risk Engine: a model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clin Sci 2001 101 : 671 679.
34. Kothari V, Stevens RJ, Adler AI et al. UKPDS 60: risk of stroke in Type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002 33 : 1776 1781.
35. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991 121 : 293 298.
36. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997 20 : 725 734.
37. Roach P, Marrero D. A critical dialogue: communicating with Type 2 diabetes patients about cardiovascular risk. Vasc Health Risk Manag 2005 1 : 301 307.
38. The Mount Hood Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007 30 : 1638 1646.
39. Ezenwaka CE, Nwagbara E, Seales D et al. Prediction of 10-year coronary heart disease risk in Caribbean Type 2 diabetic patients using the UKPDS risk engine. Int J Cardiol 2008 10.
40. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham N, Wolffenbuttel B, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000 24 : 6 11.
41. Glumer C, Yuyun M, Griffin S et al. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006 49 : 1536 1544.
42. Shearer AT, Bagust A, Liebl A, Schoeffski O, Goertz A. Cost-effectiveness of rosiglitazone oral combination for the treatment of Type 2 diabetes in Germany. Pharmacoeconomics 2006 24 : 35 48.
43. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003 26 : 2777 2784.
44. Yang X, So WY, Kong AP et al. Development and validation of a total coronary heart disease risk score in Type 2 diabetes mellitus. Am J Cardiol 2008 101 : 596 601.
45. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003 11 : 3093 3101.
46. Ridker P, Buring J, Rifai N, Cook N. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. J Am Med Assoc 2007 297 : 611 619.
47. Clarke PM, Gray AM, Briggs A et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the UK Prospective Diabetes Study Outcomes Model (UKPDS 68). Diabetologia 2004 47 : 1747 1759.
48. Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mateing 2002 22 : 340 349.
49. Diabetes Trials Unit. Website. Available at http://www.dtu.ox.ac.uk Last accessed 5 March 2008.